Primary Antiphospholipid Syndrome Clinical Trial
Official title:
Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome
Verified date | October 2018 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic
thrombosis and bad obstetric history. APS secondary to another medical disorder is the most
common. Visual and ocular changes e.g. vaso-occlusive disease of retinal and choroidal
vessels are found in patients with secondary APS. Patients with primary APS have also been
reported to have ocular changes e.g. retinal vascular occlusion
The aim of our study to detect prevalence of ocular changes in women diagnosed with primary
APS and correlation of these changes with adverse obstetric outcome. If a correlation is
present, ocular findings in women with APS could be used in the future as a predictor for
poor obstetric outcome.
Status | Completed |
Enrollment | 50 |
Est. completion date | October 23, 2018 |
Est. primary completion date | October 10, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Age: 18 to 35 years - Females with primary antiphospholipid syndrome Exclusion Criteria: - Age: below 18 years and above 35 years - Auto-immune diseases e.g. SLE and other connective tissue disease - Medical diseases causing retinal vascular changes e.g. hypertension, diabetes mellitus, sickle cell anemia. - Previous vitreo-retinal surgery |
Country | Name | City | State |
---|---|---|---|
Egypt | Cairo University | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of Ocular changes in females with antiphospholipid syndrome | Number of participants with ocular findings detected by ophthalmological examination | On the same day of enrollment into the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01956188 -
Omega 3 in LES and APS
|
N/A | |
Recruiting |
NCT05904301 -
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
|
||
Not yet recruiting |
NCT03540810 -
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome
|
Phase 3 |